Journal article
Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?
Schizophrenia research, Vol.193, pp.263-268
03/2018
DOI: 10.1016/j.schres.2017.06.059
PMID: 28734907
Abstract
Understanding the biological processes that underlie why patients relapse is an issue of fundamental importance to the detection and prevention of relapse in schizophrenia. Brain Derived Neurotrophic Factor (BDNF), a facilitator of brain plasticity, is reduced in patients with schizophrenia. In the present study, we examined whether decreases in plasma BDNF levels could be used as a biological predictor of relapse in schizophrenia. A total of 221 patients were prospectively evaluated for relapse over 30months in the Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared to Injectables: eValuating Efficacy (PROACTIVE) study. Serial blood samples were collected at a maximum of 23 time points during the 30-month trial and BDNF levels were measured in plasma samples by ELISA. Receiver Operating Characteristic (ROC) curve analysis indicated that BDNF was not a significant predictor of relapse, hospitalization or exacerbation. Regardless of treatment group (oral second generation antipsychotic vs. long-acting injectable risperidone microspheres), baseline BDNF value did not differ significantly between those who experienced any of the adverse outcomes and those who did not. While contrary to the study hypothesis, these robust results offer little support for the use of plasma BDNF alone as a biomarker to predict relapse in schizophrenia.
Details
- Title: Subtitle
- Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?
- Creators
- Anilkumar Pillai - Augusta UniversityNina R Schooler - SUNY Downstate Medical CenterDiya Peter - Augusta UniversityStephen W Looney - Augusta UniversityDonald C Goff - Nathan Kline Institute for Psychiatric ResearchAlexander Kopelowicz - David Geffen School of Medicine at University of California-Los Angeles, CA, United StatesJohn Lauriello - University of MissouriTheo Manschreck - Beth Israel Deaconess Medical CenterAlan Mendelowitz - Feinstein Institute for Medical ResearchDel D Miller - University of IowaJoanne B Severe - National Institutes of HealthDaniel R Wilson - University of FloridaDonna Ames - University of California, Los AngelesJuan Bustillo - University of New MexicoJohn M Kane - Feinstein Institute for Medical ResearchPeter F Buckley - Augusta University
- Resource Type
- Journal article
- Publication Details
- Schizophrenia research, Vol.193, pp.263-268
- Publisher
- Elsevier B.V
- DOI
- 10.1016/j.schres.2017.06.059
- PMID
- 28734907
- ISSN
- 0920-9964
- eISSN
- 1573-2509
- Grant note
- DOI: 10.13039/501100003653, name: National Institute of Health, award: U01MH070011-S1; DOI: 10.13039/100000025, name: National Institute of Mental Health, award: U01MH070011
- Language
- English
- Date published
- 03/2018
- Academic Unit
- Psychiatry
- Record Identifier
- 9984280838602771
Metrics
20 Record Views